-
Court Denies Generic Drug Manufacturer’s Motion to Dismiss Hatch-Waxman Patent Infringement Action on Jurisdiction Grounds
the United States District Court for the Southern District of Indiana joined the District of Delaware and Eastern District...
-
Brand owners file packaging patents – Courtesy (Packaging Digest)
Wm. Bolthouse Farms, Inc., Bakersfield, CA, inventive container permits point-of-use mixing of separate, compartmentalized ingredients without rupturing the main...
-
Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment
1-s2-0-s0047272710001751-mainDownload
-
FDA Announces Major Proposed Rule Amending Hatch-Waxman Regulations – Courtesy (Hogan Lovells)
On February 6, 2015, the Food and Drug Administration (FDA) published in the Federal Register (FR) a comprehensive proposed...
-
Telmisartan: no double-dipping says CJEU, as it avoids answering all the questions – Courtesy (The SPC Blog)
The Court of Justice of the European Union (CJEU) delivered its ruling in Case C‑577/13, Actavis Group PTC EHF, Actavis UK...
-
Channel strategy and orphan drugs – Courtesy (PMLiVe)
Channel strategy and orphan drugsA channel strategy is a plan for guiding decisions about a product’s distribution channel, ie...
-
Evergreening, patent challenges, and effective market life in pharmaceuticals
1-s2-0-s0167629612000057-mainDownload
-
The face of the patent is not the ‘‘Whole Story’’: determining effective life of a pharmaceutical patent in the United States
1-s2-0-s0172219004000675-mainDownload
